Back to Journals » OncoTargets and Therapy » Volume 11

New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib

Authors Koelblinger P, Lang R

Received 3 July 2018

Accepted for publication 22 October 2018

Published 23 November 2018 Volume 2018:11 Pages 8327—8340

DOI https://doi.org/10.2147/OTT.S135650

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Yao Dai


Peter Koelblinger, Roland Lang,

Department of Dermatology, Paracelsus Medical University, Salzburg, Austria

Abstract: Basal cell carcinoma (BCC) is the most common form of skin cancer worldwide. Although most BCCs can be treated by relatively simple surgical or nonsurgical methods, some patients with BCC may eventually develop advanced disease which can either be locally destructive or even include metastatic spread. The present review summarizes the current literature on the treatment of both early and advanced BCC with a focus on the hedgehog inhibitor vismodegib which has become an integral part of the management of patients with advanced BCC since its regulatory approval in 2012.

Keywords: basal cell carcinoma, treatment, PTCH1, hedgehog inhibitor
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]